Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
Boehringer Ingelheim
Johnson and Johnson
McKesson

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR TAMOXIFEN CITRATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tamoxifen Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002460 ↗ Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer Unknown status Cancer Research UK Phase 3 1987-09-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer.
NCT00002528 ↗ Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer Completed International Breast Cancer Study Group Phase 3 1993-05-01 RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast cancer cells. It is not yet known if surgery to remove breast cancer is more effective with or without lymph node removal. PURPOSE: Randomized phase III trial to compare the effectiveness of breast surgery with or without removal of axillary lymph nodes in treating women who have stage I or stage IIA breast cancer.
NCT00002529 ↗ Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer Completed International Breast Cancer Study Group Phase 3 1993-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer.
NCT00002542 ↗ Tamoxifen in Treating Women With High-Risk Breast Cancer Completed NCIC Clinical Trials Group Phase 3 1993-07-20 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.
NCT00002579 ↗ Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer Completed Scottish Cancer Therapy Network Phase 3 1993-03-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining combination chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without tamoxifen in treating women with stage I or stage II breast cancer that can be surgically removed.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tamoxifen Citrate

Condition Name

Condition Name for Tamoxifen Citrate
Intervention Trials
Breast Cancer 79
Stage IIIB Breast Cancer 9
Stage IIIA Breast Cancer 8
Stage IV Breast Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tamoxifen Citrate
Intervention Trials
Breast Neoplasms 92
Carcinoma 14
Carcinoma in Situ 11
Carcinoma, Intraductal, Noninfiltrating 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tamoxifen Citrate

Trials by Country

Trials by Country for Tamoxifen Citrate
Location Trials
United States 887
Canada 86
United Kingdom 61
Australia 21
China 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tamoxifen Citrate
Location Trials
California 31
Illinois 26
Maryland 24
Minnesota 24
Texas 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tamoxifen Citrate

Clinical Trial Phase

Clinical Trial Phase for Tamoxifen Citrate
Clinical Trial Phase Trials
Phase 4 4
Phase 3 57
Phase 2/Phase 3 1
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tamoxifen Citrate
Clinical Trial Phase Trials
Completed 66
Unknown status 25
Active, not recruiting 17
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tamoxifen Citrate

Sponsor Name

Sponsor Name for Tamoxifen Citrate
Sponsor Trials
National Cancer Institute (NCI) 59
Southwest Oncology Group 11
Cancer and Leukemia Group B 9
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tamoxifen Citrate
Sponsor Trials
Other 215
NIH 59
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
AstraZeneca
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.